1 – 10 of 77
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines
(
- Contribution to journal › Article
- 2015
-
Mark
Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model.
(
- Contribution to journal › Article
- 2014
-
Mark
Change in Cell Death Markers During (177)Lu-mAb Radioimmunotherapy-Induced Rejection of Syngeneic Rat Colon Carcinoma.
(
- Contribution to journal › Article
-
Mark
Sequential Radioimmunotherapy with (177)Lu- and (211)At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
- 2013
-
Mark
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.
(
- Contribution to journal › Article
-
Mark
The Intratumoral Distribution of Radiolabeled 177Lu-BR96 Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
-
Mark
Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
(
- Contribution to journal › Article
- 2012
-
Mark
Repeated Radioimmunotherapy with (177)Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
-
Mark
Pattern of antigen expression in metastases after radioimmunotherapy of a syngeneic rat colon carcinoma utilizing the BR96 antibody.
(
- Contribution to journal › Article
-
Mark
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
(
- Contribution to journal › Article